Yes, Neurontin (gabapentin) significantly increases the risk of falls, particularly in older adults and at higher doses.
Key Evidence from Guidelines and FDA Labeling
The 2019 American Geriatrics Society (AGS) Beers Criteria explicitly identifies gabapentin as a fall risk medication 1. The guidelines specifically warn about:
- Drug-drug interactions: Concurrent use of gabapentin with opioids substantially increases fall risk and should be avoided except when transitioning from opioids to gabapentin 1
- CNS-active drug combinations: Using three or more CNS-active drugs (including gabapentin, antidepressants, antipsychotics, benzodiazepines, and opioids) increases fall risk 1
- Clinically significant fall risk in older adults, with death listed as a potential outcome 1
The FDA drug label for Neurontin clearly warns that gabapentin causes dizziness, somnolence, and CNS depression 2. Patients are explicitly advised not to drive or operate machinery until they understand how the drug affects them. The label emphasizes increased CNS depression risk when combined with morphine 2.
Dose-Response Relationship
The fall risk increases with dose:
- Doses ≥600 mg/day: Clinicians should actively monitor for safety concerns 3
- Doses >300 mg/day: Associated with 50% higher risk of falls and 38% higher risk of fractures 3
- Even lower doses (>100-300 mg/day): Still associated with 26-30% increased fall hazard 3
Magnitude of Risk
Recent high-quality research provides specific risk estimates:
- Overall fall risk: Gabapentin increases fall/fracture incidence by 35% (RR 1.35) compared to unexposed patients 3
- Altered mental status: 12% increased risk (RR 1.12) 3
- Highest doses (≥2,400 mg/day): Nearly double the fall/fracture risk (RR 1.90) 3
- Combined with opioids: 73% increased fall risk (AOR 1.73) in older adults 4
Important Nuances
One 2025 study comparing gabapentin to duloxetine found gabapentin had lower fall risk (HR 0.52) 5. However, this doesn't mean gabapentin is safe—it means duloxetine carries even higher fall risk. This study compared two fall-risk medications against each other, not against no treatment.
Special populations at elevated risk:
- Hemodialysis patients: 50-55% higher hazard of falls even at lower doses due to impaired renal clearance 6
- Older adults ≥65 years: Baseline higher fall risk compounded by medication effects 4, 3
- Patients with multiple comorbidities: Already elevated fall risk further increased 4
Clinical Implications
When prescribing gabapentin, you must:
- Start at the lowest effective dose and titrate slowly, especially in older adults
- Avoid combining with opioids whenever possible—this combination substantially increases fall risk 1, 4
- Minimize total CNS-active drug burden—avoid using ≥3 CNS-active medications simultaneously 1
- Monitor closely for dizziness, somnolence, and ataxia, particularly in the first weeks of therapy 2
- Counsel patients explicitly about fall risk and advise against driving until effects are known 2
- Consider dose reduction in renal impairment—gabapentin is renally cleared and accumulates, dramatically increasing toxicity risk 6
Common Pitfalls to Avoid
- Don't assume "low doses are safe": Even doses of 100-300 mg/day increase fall risk by 26-31% 3
- Don't overlook drug interactions: The combination of gabapentin + opioids is specifically flagged in the Beers Criteria as high-risk 1
- Don't forget renal dosing: Failure to adjust for kidney function leads to drug accumulation and increased adverse events 6
- Don't ignore cognitive effects: Gabapentin is associated with altered mental status, which independently increases fall risk 3, 7
The evidence is clear and consistent across guidelines, FDA labeling, and multiple high-quality studies: gabapentin increases fall risk in a dose-dependent manner, particularly in older adults and when combined with other CNS-active medications. This risk must be weighed against therapeutic benefits, with careful monitoring and dose optimization essential for patient safety.